DeepMed Research

Guangdong Association of Clinical Trials

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 1997-01-01

Employees: -

Market Cap: -

Website: http://gdaids.org

Clinical Trials

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

Phase 3

Not yet recruiting

Conditions: Neoadjuvant Non-Small Cell Lung Cancer

Interventions: Drug: lorlatinib
Other: concurrent/sequential platinum-based chemoradiotherapy

First Posted Date: 2025-03-05

Last Posted Date: 2025-03-05

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 36

Registration Number: NCT06858410

Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC

Not Applicable

Not yet recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Osimertinib
Drug: Alectinib
Drug: TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy

First Posted Date: 2024-11-29

Last Posted Date: 2024-11-29

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 342

Registration Number: NCT06709274

Locations: 🇨🇳
Dongguan People's Hospital, Dongguan, Guangdong, China
🇨🇳
The First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳
Guangdong Provincial People's Hostpital, Guangzhou, Guangdong, China

and more 12 locations

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Phase 4

Not yet recruiting

Conditions: Carcinoma, Non-Small-Cell Lung
Brain Metastases
Leptomeningeal Metastasis

Interventions: Drug: Lorlatinib

First Posted Date: 2024-02-28

Last Posted Date: 2024-02-28

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 50

Registration Number: NCT06282874

Locations: 🇨🇳
Guangdong Provincial Perople's Hospital, Guangzhou, Other (Non U.s.), China

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Phase 2

Recruiting

Conditions: ALK Positive Non-small Cell Lung Cancer

Interventions: Drug: Loratinib

First Posted Date: 2023-10-23

Last Posted Date: 2023-10-23

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 126

Registration Number: NCT06092086

Locations: 🇨🇳
Guangdong Provincial Perople's Hospital, Guangzhou, Guangdong, China

Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

Phase 2

Recruiting

Conditions: Small-cell Lung Cancer

Interventions: Drug: Serplulimab
Drug: SOC

First Posted Date: 2023-07-24

Last Posted Date: 2024-02-22

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 36

Registration Number: NCT05957510

Locations: 🇨🇳
Guangdong Provincial Perople's Hospital, Guangzhou, Guangdong, China

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

Phase 2

Recruiting

Conditions: MRD

Interventions: Genetic: Adjuvant treatment for MRD positivity

First Posted Date: 2022-09-13

Last Posted Date: 2022-09-14

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 180

Registration Number: NCT05536505

Locations: 🇨🇳
Chongqing University Three Gorges Hospital, Chongqing, China
🇨🇳
The First People's Hospital of Foshan, Foshan, China
🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China

and more 13 locations

Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD

Recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Diagnostic Test: Molecular residual disease test

First Posted Date: 2022-07-13

Last Posted Date: 2022-09-29

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 180

Registration Number: NCT05457049

Locations: 🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China

Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC

Phase 2

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Osimertinib
Drug: Savolitinib

First Posted Date: 2021-12-20

Last Posted Date: 2024-02-09

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 44

Registration Number: NCT05163249

Locations: 🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China

Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC

Phase 2

Not yet recruiting

Conditions: Lung Cancer

Interventions: Drug: Osimertinib
Drug: Bevacizumab

First Posted Date: 2021-08-03

Last Posted Date: 2021-08-03

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 90

Registration Number: NCT04988607

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model.

Phase 3

Recruiting

Conditions: Lung Cancer

Interventions: Drug: Almonertinib

First Posted Date: 2021-04-12

Last Posted Date: 2023-11-18

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 192

Registration Number: NCT04841811

Locations: 🇨🇳
Guangdong Lung cancer institute, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy